Circulating tumor cells (CTCs) are cancer cells that detach from a primary cancer tumor and enter a person’s bloodstream. Their goal is to move to another part of the body to form new metastases. These new metastatic lesions are more aggressive than the primary tumor and account for most of the cancer-related deaths.
At the recent ASCO meeting there were two abstracts presented that discuss two potential clinical trial endpoints for survival. If they can be validated it would save research money and move FDA drug approval at a faster pace.